Search

Your search keyword '"Guo, Xiao Zhong"' showing total 168 results
Start Over Author "Guo, Xiao Zhong"
168 results on '"Guo, Xiao Zhong"'

10. Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

Author

Jiang Chen, Guo Xiao-Zhong, and Xing-Shun Qi

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Specific immunotherapies, including vaccines with autologous tumor cells and tumor antigen-specific monoclonal antibodies, are important treatments for PC patients. To evaluate the clinical outcomes of PC-specific immunotherapy, we performed a systematic review and meta-analysis of the relevant published clinical trials. The effects of specific immunotherapy were compared with those of nonspecific immunotherapy and the meta-analysis was executed with results regarding the overall survival (OS), immune responses data, and serum cancer markers data. The pooled analysis was performed by using the random-effects model. We found that significantly improved OS was noted for PC patients utilizing specific immunotherapy and an improved immune response was also observed. In conclusion, specific immunotherapy was superior in prolonging the survival time and enhancing immunological responses in PC patients.

Published
2017
Full Text
View/download PDF

14. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma

Author

Zheng Guo-Qi, Song Hui, Guo Xiao-Zhong, Yang Dong-Liang, Liang Yu-Fei, and Liu Chun-Rong

Subjects
Adult, Male, Mesothelioma, 0301 basic medicine, medicine.medical_specialty, Lung Neoplasms, Receptors, Cytoplasmic and Nuclear, Risk Assessment, Gastroenterology, Pathology and Forensic Medicine, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Biomarkers, Tumor, medicine, Humans, Peritoneal Neoplasms, Aged, Neoplasm Staging, Aged, 80 and over, Univariate analysis, biology, business.industry, Proportional hazards model, Mesothelioma, Malignant, Microfilament Proteins, Hazard ratio, Univariate, RNA-Binding Proteins, Middle Aged, medicine.disease, Immunohistochemistry, Confidence interval, Ki-67 Antigen, 030104 developmental biology, 030220 oncology & carcinogenesis, Ki-67, Trans-Activators, biology.protein, Peritoneal mesothelioma, Female, business
Abstract

Malignant peritoneal mesothelioma (MPeM) is an incurable cancer with poor prognosis, and several biomarkers have been suggested for screening of MPeM. The aim of our study was to evaluate the prognostic significances of IMP3 and Fli-1 in MPeM. Diagnostic biopsies of 44 MPeM patients were centrally collected and were immunohistochemically analyzed for expression of IMP3, Fli-1, and Ki-67. Labeling was assessed by 2 pathologists. Complete clinical information and follow-up were obtained from patients' records. Carcinomas expressed Fli-1 in 42 (95.5%) of 44 specimens, and IMP3 in 23 (52.3%) of 44 specimens. Spearman ρ analysis revealed that Fli-1 expression was related to both histologic type and Ki-67 labeling index (Ki-67LI; r = -0.500, P < .05; r = 0.358, P < .05), and IMP3 expression was related to Ki-67LI (r = 0.401, P < .05). A Kaplan-Meier analysis and univariate Cox regression analysis showed that tumor-directed treatment, a lower peritoneal carcinomatosis index, stage I, lower Ki-67LI, and lower level of IMP3 expression had a statistically significantly positive effect on overall survival; Fli-1 did not affect overall survival in the univariate analysis (hazard ratio [HR], 1.026; P = .904). A Kaplan-Meier analysis showed the correlation between IMP3-Fli-1 and overall survival, whereas univariate and multivariate Cox regression analyses did not confirm the correlation. Cox regression analysis revealed that IMP3 expression (HR, 2.311 [95% confidence interval, 1.190-4.486]; P = .013) and no tumor-directed treatment (HR, 0.189 [95% confidence interval, 0.086-0.416]; P = .000) retained independent prognostic significance, both with negative effect on OS. IMP3, along with tumor-directed treatment protocols, is a powerful prognosticator in patients with MPeM.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results